OnCo
technologiesTechnologyConcept

Epigenetic editing (durable gene silencing)

Switching a gene off for good without changing the DNA sequence, by writing chemical marks onto it.

CRISPRoff-style effectors fuse a dead Cas protein to DNA methyltransferase and repressor domains, imposing heritable silencing that survives cell division. Tune Therapeutics and Chroma Medicine took the approach into the clinic in hepatitis B, not cancer. In oncology it is an attractive route to silence undruggable drivers such as MYC, but no oncology trial had been registered by September 2026, and silencing would have to reach essentially every tumour cell to matter.

Generic schematic · not to scale · placeholder for the epigenetics front
Histones · Marks read / written / erased

How it works

dCas9 fused to DNMT3A/3L and KRAB deposits CpG methylation and repressive histone marks at a promoter; the silenced state is copied to daughter cells.

Strengths
  • No DNA cut, so no translocation risk
  • Potentially reversible
  • Reaches transcription factors that have no drug pocket
Limitations
  • No oncology trial yet (2026)
  • Delivery to solid tumours unsolved
  • Escape by cells that lose the mark or the dependency

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Epigenetic editing" OR ABSTRACT:"Epigenetic editing" OR TITLE:"durable gene silencing" OR ABSTRACT:"durable gene silencing") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Epigenetic editing (durable gene silencing), not a curated reading list.

Connected

6top